Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis.
Gabriele RoccuzzoFederica RepettoSilvia GiordanoCristina SardaArianna ComesPaolo DapavoPietro QuaglinoSimone RiberoPublished in: Experimental dermatology (2024)
Real-world data on the long-term effectiveness of the anti-IL17 agent secukinumab in treating moderate-to-severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate-severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12-week intervals. The median secukinumab drug survival was 16.0 months (range 3-51), with a 56.5% maximal response rate at 6 months and dropout exceeding 40% at 1 year. Baseline disease burden emerged as a key predictor of treatment response, overshadowing factors like sex or BMI. Prior systemic steroid use negatively impacts drug survival. The study underscores the critical 6-month window for assessing treatment efficacy, emphasizing the importance of initial induction dosing. Additionally, the newly developed scoring system, IHS4-55, showed analogies to the older HiSCR score in capturing treatment response. In this real-life scenario, challenges persist in HS management, necessitating innovative therapeutic approaches and predictive markers.
Keyphrases
- hidradenitis suppurativa
- ankylosing spondylitis
- systematic review
- high intensity
- early onset
- free survival
- type diabetes
- body mass index
- physical activity
- metabolic syndrome
- emergency department
- heart rate
- blood pressure
- systemic lupus erythematosus
- adipose tissue
- ultrasound guided
- disease activity
- rheumatoid arthritis
- weight loss
- big data
- insulin resistance
- body composition
- platelet rich plasma
- study protocol
- data analysis
- skeletal muscle
- combination therapy